Actelion Pharmaceuticals Australia

Actelion Pharmaceuticals Australia is a specialized biopharmaceutical company and a subsidiary of Johnson & Johnson, dedicated to transforming the lives of patients with pulmonary arterial hypertension (PAH) and other rare diseases. Originally part of the Swiss-based Actelion Pharmaceuticals, the company was acquired by Johnson & Johnson in 2017 and integrated into the Janssen Pharmaceutical Companies. The Australian division focuses on the commercialization and medical support of a market-leading portfolio, including endothelin receptor antagonists and prostacyclin pathway therapies. Key products such as Opsumit, Uptravi, and Tracleer have established the company as a leader in the cardiovascular and orphan drug sectors. Actelion's legacy is defined by its transition from a biotech startup to a global powerhouse in pulmonary medicine.